

Title: Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies

Authors: Daniel Reichart^{1,2,3#}, Eric L. Lindberg^{4#^}, Henrike Maatz^{4,5#}, Antonio M.A. Miranda^{6,7}, Anissa Viveiros^{8,9}, Nikolay Shvetsov⁴, Anna Gärtner¹⁰, Emily R. Nadelmann¹, Michael Lee⁶, Kazumasa Kanemaru¹¹, Jorge Ruiz-Orera⁴, Viktoria Strohmenger^{1,12}, Daniel M. DeLaughter^{1,13}, Giannino Patone⁴, Hao Zhang^{8,9}, Andrew Woehler¹⁴, Christoph Lippert^{15,16}, Yuri Kim^{1,2}, Eleonora Adami⁴, Joshua M. Gorham¹, Sam N. Barnett⁶, Kemar Brown^{1,17}, Rachel J. Buchan^{6,18}, Rasheda A. Chowdhury⁶, Chrystalla Constantinou⁶, James Cranley¹¹, Leanne E. Felkin^{6,18}, Henrik Fox¹⁹, Ahla Ghauri²⁰, Jan Gummert¹⁹, Masatoshi Kanda^{4,21}, Ruoyan Li¹¹, Lukas Mach^{6,18}, Barbara McDonough^{2,13}, Sara Samari⁶, Farnoush Shahriaran²², Clarence Yapp²³, Caroline Stanasiuk¹⁰, Pantazis I. Theotokis^{6,24}, Fabian J. Theis²², Antoon van den Bogaerdt²⁵, Hiroko Wakimoto¹, James S. Ware^{6,18,24}, Catherine L. Worth⁴, Paul J.R. Barton^{6,18,24}, Young-Ae Lee^{20,26}, Sarah A. Teichmann^{11,27}, Hendrik Milting^{10#}, Michela Nosedà^{6,7#}, Gavin Y. Oudit^{8,9#}, Matthias Heinig^{22,28,29#}, Jonathan G. Seidman^{1#^}, Norbert Hubner^{4,5,30#^}, Christine E. Seidman^{1,2,12#^}

Affiliations:

1. Department of Genetics, Harvard Medical School, Boston MA, 02115 USA
2. Cardiovascular Division, Brigham and Women's Hospital Boston MA, 02115 USA
3. Department of Medicine I, University Hospital, LMU Munich, 80336 Munich, Germany
4. Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany
5. DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany
6. National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK
7. British Heart Foundation Centre for Research Excellence and Centre for Regenerative Medicine, Imperial College London WC2R 2LS, UK
8. Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2R3, Canada

9. Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
10. Erich and Hanna Klessmann Institute, Heart and Diabetes Center NRW, University Hospital of the Ruhr-University Bochum, 32545 Bad Oeynhausen, Germany
11. Cellular Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, UK
12. Walter-Brendel-Centre of Experimental Medicine, Ludwig-Maximilian University of Munich, 81377 Munich, Germany
13. Howard Hughes Medical Institute, Bethesda MD, 20815-6789, USA
14. Systems Biology Imaging Platform, Berlin Institute for Medical Systems Biology (BIMSB), Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 10115 Berlin, Germany
15. Digital Health-Machine Learning group, Hasso Plattner Institute for Digital Engineering, University of Potsdam, 14482 Potsdam, Germany
16. Hasso Plattner Institute for Digital Health, Icahn School of Medicine at Mount Sinai, NY 10029, USA
17. Cardiac Unit, Massachusetts General Hospital, Boston, MA 02114, USA
18. Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NR, UK
19. Heart and Diabetes Center NRW, Clinic for Thoracic and Cardiovascular Surgery, University Hospital of the Ruhr-University, 32545 Bad Oeynhausen, Germany
20. Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany
21. Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan
22. Computational Health Center, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), 85764 Neuherberg, Germany
23. Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA
24. MRC London Institute of Medical Sciences, Imperial College London, London W12 0NN, UK
25. ETB-Bislife Foundation, POB 309, 2300 AH Leiden, The Netherlands.

26. Clinic for Pediatric Allergy, Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, 13125 Berlin, Germany
27. Department of Physics, Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, UK
28. Department of Informatics, Technische Universität München (TUM), 85748 Munich, Germany
29. DZHK (German Centre for Cardiovascular Research), Munich Heart Association, Partner Site Munich, 10785 Berlin, Germany
30. Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany

Denotes equal contribution

^ Corresponding authors: Eric L. Lindberg: eric.lindberg@mdc-berlin.de

Jonathan Seidman: seidman@genetics.med.harvard.edu

Norbert Hubner: nhuebner@mdc-berlin.de

Christine Seidman: cseidman@genetics.med.harvard.edu

Abstract: Pathogenic variants in genes that cause dilated (DCM) and arrhythmogenic cardiomyopathies (ACM) convey high risks for the development of heart failure through unknown mechanisms. Using single nucleus RNA sequencing (snRNAseq), we characterized the transcriptome of 880,000 nuclei from 18 control and 61 failing, non-ischemic human hearts with pathogenic variants in DCM and ACM genes or idiopathic disease. We performed genotype-stratified analyses of the ventricular cell lineages and transcriptional states. The resultant DCM and ACM ventricular cell atlas demonstrated distinct right and left ventricular responses, highlighting genotype-associated pathways, intercellular interactions, and differential gene expression at single cell resolution. Together these data illuminate both shared and distinct cellular and molecular architectures of human heart failure and suggest candidate therapeutic targets.

One-Sentence Summary: Single nucleus analyses define ventricular responses in human cardiomyopathies with pathogenic variants.

Main Text:

Introduction

Dilated cardiomyopathy (DCM), a prevalent disorder occurring in 1:250 individuals, is characterized by left ventricular (LV) dilatation, cardiomyocyte loss with fibrotic replacement, and impaired contractility (1). Arrhythmogenic cardiomyopathy (ACM) similarly incites ventricular dysfunction, often with more prominent right ventricular (RV) involvement, high arrhythmogenic burden, and fibrofatty accumulations (2). Both disorders can arise from genetic causes (1, 2). DCM genes encode proteins involved in contractility (titin; *TTN*, troponin T; *TNNT2*, troponin C; *TNNC1*, tropomyosin; *TPM1*, and filamin C; *FLNC*), that regulate cardiac splicing (RNA-binding motif protein; *RBM20*) or calcium sequestration (phospholamban; *PLN*), and maintain cytoskeletal (desmin; *DES*) or nuclear (lamin A/C; *LMNA*) integrity. ACM genes often encode desmosome proteins including plakophilin-2 (*PKP2*) and desmoplakin (*DSP*). The cardiomyocyte-specific expression and damaging effects of pathogenic variants (PVs) in many DCM and ACM genes propel the development of arrhythmias and heart failure (HF), a highly morbid condition affecting 23 million individuals worldwide (3).

We hypothesized that PVs in different genes would evoke distinct single-cell molecular phenotypes. To address this, we studied the molecular signals underlying HF pathogenesis using snRNAseq of human hearts with advanced DCM and ACM compared to non-failing donor (control) hearts. We revealed differences in the cellular landscape and transcriptional changes between several DCM and ACM genotypes. By leveraging machine learning approaches we illuminated genotype-specific molecular responses, as validated by reconstructing the underlying PVs using snRNAseq data.

Results

Study Cohort

We studied LV and RV tissues (Fig. 1A), obtained prior to any mechanical support in 61 patients and 18 controls (Tables S1, S2) including 12 controls previously reported (4). Thirty-eight independent PVs were identified in three DCM genes (*LMNA*; n=12, *RBM20*; n=8, *TTN*; n=12) and in the ACM gene *PKP2* (n=6), while no PVs were detected in eight DCM patients (PVneg) (Fig. 1B). Analyses were performed for these five genotypes individually (n=46), for aggregated DCM genotypes (*LMNA*, *RBM20*, *TTN*, PVneg), ACM (*PKP2*), and controls. Additionally, we generated data from 15 PVs across *PLN*, *BAG3*, *DES*, *FLNC*, *FKTN*, *TNNC1*, *TNNT2*, *TMP1*, and *DSP* (Table S1, S2). Due to few recurrent PVs, these genes were excluded in downstream analyses, except where indicated.

Males predominated among patients (60%) and controls (72%) (Fig. S1A). The mean age of patients was 48.4±4.3 years exclusive of *RBM20* (mean age 32.9±14.6 years). Clinical manifestations indicated similar LV dysfunction in *LMNA*, *TTN*, and PVneg patients, but greater LV dilatation and reduced systolic contraction in *RBM20*, and preserved LV with reduced RV function in *PKP2*. *LMNA* and *TTN* patients received more pacemaker/resynchronization therapies than those with other genotypes (Table S1).

Disease-associated compositional changes of cell types

Nuclei were isolated as described (4) from full thickness LV free wall (FW), apex (AP), septum (S) and RV free wall (RV) (Fig. 1C). We compared ~500,000 high-quality nuclei from patients' ventricular tissues and ~380,000 nuclei from controls (Fig. S1B-E). After pre-processing and quality control filtering, data were integrated across samples using Harmony prior to constructing manifolds using Uniform Manifold Approximation and Projections (UMAPs). Clustering identified ten major cardiac cell types encompassing ventricular cardiomyocytes (CM), fibroblasts (FB), adipocytes (AD), pericytes and smooth muscle cells (mural, MC), endothelial (EC), myeloid and lymphoid (immune), neuronal (NC) and mast cells (Figs. 1C) with 71 distinct cell states. States of the same cell type shared a transcriptional profile but also expressed distinct genes, which implied biological differences.

Cell type abundances in sample replicates were highly correlated (Pearson coefficient 0.74 - 0.99) (Figs. S2A, B). Cell composition, states, and transcript counts across the FW, AP,

and S showed high similarities, and therefore are reported grouped together as LV (Figs. S2C, D).

Using center log ratio- (CLR) transformed abundance of cell types, we considered the effects of sex on LV and RV cell compositions in DCM (10 female, 29 male) and control (7 female, 11 male) hearts (Fig. S2E). Myeloid cells showed a modest sex-specific difference (FDR=0.016). Only *LMNA* tissues (from 7 males, 5 females) were sufficient for genotype-specific, sex-associated analyses. Female LV myeloid cells were increased (FDR 0.05), paralleling the findings in DCM vs controls. In addition, RV endothelial cells showed a modest female-specific increase between *LMNA* patients and controls (FDR 0.048).

The proportions of LV nuclei across the genotypes demonstrated depletion of CMs except in *LMNA*, and increased ECs and immune cells except in *PKP2* (Figs. 1D, S3). In RVs (Fig. S4), CMs were depleted in the DCM subgroup except for *TTN*, while ECs were increased in *LMNA*, *TTN*, and *RBM20*, and immune cells were not changed. FBs were not increased in LVs and RVs (Figs. 1D), despite histopathological findings of fibrosis, which implied the acquisition of a secretory rather than a proliferative phenotype.

Individual-level abundances for cell types (LV, Table S3; RV, Table S4) and cell states (Table S5) are provided for controls and patients. Different cell type abundances in disease compared to control LVs remained significant using a linear model adjusting for age. Pairwise cell type ratios in disease LVs compared to controls confirmed loss of CMs and showed accompanying increased ECs, lymphoid and myeloid cells, and altered ratios (FB and mural compared to CM) with quantitative, genotype-specific differences (Figs. 1E). *RBM20* and PVneg, respectively showed greatest shifts in EC:CM (8- and 10.3-fold), myeloid:CM (9.8- and 14.6-fold), and lymphoid:CM (12.4- and 15.2-fold). By contrast, pairwise ratios of all cell types compared to CM were modest or unchanged in *LMNA*.

Genotypes diversify cell types and states

Cardiomyocytes

Disease and control ventricles exhibited the previously described (vCM1.0-5; (4)) and four new cardiomyocyte states: vCM1.1, 1.2, 1.3, 3.1 (Fig. 2A-B, Table S6). Across all vCM cell states (Fig. S5), differentially expressed genes (DEGs) in disease connoted increased stress (for

example, *NPPB*) and apoptosis (Tables S7-12, Fig. S6A). While these findings implied late-stage transcriptional convergence, 20-40% of DEGs were genotype-specific (Fig. S5). Only PVneg reduced *MYH6* expression, increasing *MYH7:MYH6* ratios (Fig. S6B). Conversely, only vCMs with PVs downregulated *SMYD1* (Figs. 2C, S6C-E, Table S13), a cardioprotective muscle-specific histone methyltransferase that regulates sarcomere assembly and mitochondrial energetics (5, 6), and *ADRB1* (β 1-adrenergic receptor; Fig. S6C) indicative of adrenergic activation, which is therapeutically targeted by β -blockade medicines (7, 8). Genotype-selective responses included upregulation of *FNIP2* (Fig. 2D), inhibiting AMP-activated protein kinase activity and oxidative metabolism (9–11) in *LMNA* and *PKP2*, and *CPEB4*, an RNA-binding protein that activates glycolysis and stimulates fibrosis (12) in *LMNA*, *RBM20*, and *PKP2* (Fig. S6F).

Proportional differences in vCM states (Figs. S6G, S7, S8) varied among genotypes and controls and were more prominent in RVs than LVs, perhaps reflecting hemodynamic differences. PVs generally increased vCM1.1 and 1.2, with accompanying decreased vCM3.1 in *LMNA* and *TTN* (Figs. 2B, S7A, S8A-D). State-enriched DEGs for vCM1.1 included *MYO18B*, required for sarcomere formation (13), *XPR1*, regulating phosphate homeostasis (14), and *IGF1R* and *ROR1*, involved in cell survival (8). vCM1.2 had heightened expression of electrophysiologic genes including *PCDH7* that enables intercellular contacts (15, 16), but when overexpressed, impedes synaptic currents (17), *CAMK2D* modulating excitation-contraction coupling (18), and *ANK2*, harboring arrhythmogenic PVs (19, 20). vCM1.3 was modestly increased in *RBM20*, associated with the largest numbers of DEGs in all genotypes, and enriched for *BMP* receptors (*BMPRIA*, *BMPR1B* (21, 22); Figs. S7B, D) and *GPC5* that regulates BMP signaling (23). vCM3.1, reduced in *LMNA* and *TTN*, expressed early-adaptive transcriptional regulators of stress responses (*ATF3*, *ATF4*) and cardioprotection (*NR4A3*; Fig. S7E) (24). Only PVneg depleted vCM2, enriched for *SH3RF2*, an anti-apoptosis regulator of the *JNK* pathway (25). As DCM and ACM genes are highly and often selectively expressed in CMs, these disease-associated vCM states and DEGs defined intrinsic responses to PVs as well as cell-cell responses to CM death, depressed contractile performance, and arrhythmogenicity.

Fibroblasts

We identified four previously characterized (4) and two new ventricular FB states (vFB1.1, vFB1.2; Fig. 2E, Table S14). Across all vFB states, upregulated DEGs included genes involved in extracellular matrix (ECM) remodeling (Figs. S9-11, Table S15-21). *LMNA*, *TTN*, and *PKP2* increased fibrogenic signaling receptor, *EGFR* and *PKP2* also increased *AGTR1* (Fig. S10A) that enables EGFR-transactivation (26, 27). The expression of profibrotic *TGFβ2* was universally increased (Fig. S10B). DCM hearts were enriched for *PCOLCE2*, promoting insoluble collagen formation (28), and *LMNA*, *TTN*, and PVneg downregulated metalloproteinase inhibitors *TIMP1* and *3* (Fig. S10C). Notably, collagen genes showed genotype-specific expression. *COL4A1* and *COL4A2* were upregulated in *LMNA*, *TTN* and *PKP2* while *COL4A5* and *COL24A1* were enriched in PVneg. Thus, although ECM upregulation and collagen deposition (Figs. 2F, S10D-F) was a shared feature, genotype and chamber influenced composition and organization.

FB state abundance was also altered across genotypes (Figs. S11A, S12A-D). vFB1.1 and vFB1.2 expressed canonical vFB1.0 genes but vFB1.1 also up-regulated *APOD*, *APOE* and *APOO*, typifying lipogenic fibroblasts (29) and *CST3* (Fig. S13A), involved in matrix remodeling. vFB1.2-enriched genes related to actin filament assembly (*DAAMI*) and chondrocyte differentiation (*GPC6*) (Fig. S13B). vFB2 expressed prominent profibrotic genes including *TGFβ*-targets (increased in DCM LVs) and fibrogenic *IL11* (30) (highest in *RBM20* LVs) (Figs. 2H, S14A-C). vFB2 was increased in *TTN* and PVneg and modestly in other DCM LVs (Figs. 2G-H, S11). vFB3, diminished in hearts with PVs, expressed proinflammatory cytokine genes (*CCL2*) and genes related to *OSM* signaling (*IL6ST*, *OSMR*, and oncostatin M-target genes) (Figs. 2I, S14D). The resultant increased ratio of vFB2:vFB3 and altered DEGs suggested dysregulation of fibroblast-to-macrophage interactions that would promote deleterious ECM remodeling, particularly in *TTN* LV and RV (Figs. S12C, D).

Smooth muscle cells and pericytes

Three previously described pericyte (PC1-3) and three smooth muscle cell states (SMC1.1, SMC1.2, SMC2, Fig. 3A, Table S22) were identified. DEGs across all states (Fig. S15, Tables S23-28) showed upregulation of the sodium channel *SCN3A*, with unknown vascular functions, and the noncoding antisense *ADAMTS9-AS2*, with concordant downregulation of

ADAMTS9, a metalloprotease involved in ECM remodeling (31, 32) (Figs. 3B, S16A). Overall DEGs implied that disease evoked signals to synthesize specific ECM and integrin components.

DEGs in PC states included downregulation of two central signaling receptors, *NOTCH3* and *PDGFRB*, in *PKP2* and *TTN* PC1 (Fig. 3B). *NOTCH3* is required for SMC maturation and deficiency causes pericyte dysfunction and arteriovenous malformations. Notch signaling regulates *PDGFRB*, necessary for angiogenesis and PC recruitment (33–37).

DEGs in SMCs subdivided the previously identified canonical SMC1 (4) into two states. SMC1.1, had higher expression of *ACTA2*, *MYH11*, and *TAGLN*. SMC1.2, strongly expressed *ITGA8*, required for maintenance of SMC contractile phenotype (38, 39), and *ATP10A*, suggesting vascular stiffness and increasing diastolic dysfunction (Fig. 3B) Methylation of the *ATP10A* locus in SMC decreases with age and atherosclerosis (40). SMC1.2 was enriched in *LMNA*, *TTN* and PVneg RVs (Figs. S17, S18). SMC2 expressed high levels of genes involved in collagen and elastic fiber formation (*ELN*, *LAMA2*) and *MYH10*, demarcating dedifferentiated SMCs with secretory properties (Figs. S16B, S17C). *LMNA* and *PKP2* SMC2 upregulated *SLIT3*, a stimulator of fibroblast activity (41), and ECM synthesis and collagen formation genes (Figs. 3B-C). Collectively, disease remodeling of MC indicated modulation of PDGF and NOTCH signaling receptors and synthesis of selective ECM and integrin components.

Endothelial cells

Characterization of ECs identified seven previously described cell states (4) (EC1, 2, 5-8 and Mesothelial) (Figs. 3D, S19-21, Table S29). Shared DEGs occurred across all and between genotypes (Table S30-35) with clear RV and LV differences (Fig. S19). Dysregulation of genes encoding factors involved in EC fate, blood vessel development and angiogenesis (*NOTCH4*, *FLT1*, *FGFR1*, *RGCC*) (42–44) in disease LVs indicated that vascular remodeling was a common HF feature.

EC composition in DCM RVs and LVs increased EC5 in comparison to controls (Fig. S21A), while genotype-specific cell state ratios in LVs generally decreased EC1 relative to EC2, EC5, and EC6 (Figs. 3F, S21C). Assessment of selective gene enrichment scores for proliferating cells, endothelial-to-mesenchymal transformation (EMT), and cell death showed no difference in disease compared to controls (Fig. S22; Table S36).

EC7 had the most DEGs and highest proportion of unique DEGs across all genotypes. Although initially defined as atrial-enriched (4) EC7 expressed endocardial-enriched genes (*SMOC1* (45), *NPR3* (46), and *POSTN* (47) (Figs. S20B-C), which prompted a revised annotation to endocardial cells. Interestingly, upregulated genes in EC7 from DCM LVs and *PKP2* RVs (Fig. 3G) encoded secreted proteins involved in myocardial stress-adaptation (*NRG1*) (48), CM force production (*EDNI*) (49, 50), and endocardial expansion during development or after cardiac injury (*BMP6*) (51, 52). Notably, *BMP6* was selectively upregulated in the endocardium of DCM LVs and ACM RVs (Fig. 3E). Conversely, *INHBA*, a TGF β superfamily member involved in atrio-ventricular canal development (53), and cell adhesion molecule *OPCML* were downregulated. In *PKP2*, an unconventional myosin promoting cell adhesion (*MYO10*), and *POSTN*, were upregulated in both ventricles. These data highlighted the involvement of the endocardium in chamber-specific remodeling of cardiomyopathies.

Myeloid cells

We classified 14 subclusters of myeloid cells comprising macrophages (MP), monocytes (MO), conventional dendritic (cDC1 and cDC2) and proliferating myeloids (Figs. 4A, S23-27, Tables S37-45). Distinct gene sets were unique to each genotype and were particularly pronounced in PVneg and *PKP2* in LVs (Fig. S24).

Although disease increased myeloid cells, the proportions of proliferating myeloids (Figs. 4B-C, S26-27) were consistently lower compared to controls, implying monocyte-infiltration. Tissue resident MPs *LYVE1*^{high}MHCII^{low} and *LYVE1*^{low}MHCII^{high} (Fig. S25C) were the most abundant myeloid cells (Figs. S27A-B). MP *LYVE1*^{low}MHCII^{high} were increased in the RV of *LMNA* with similar trends in other genotypes (Fig. S27B). Proportions of MP^{OSM} were modestly decreased with downregulation of *OSM* in *TTN* ventricles (Fig. S28A), which would attenuate the MP^{OSM}-vFB3 signaling axis (4), and mirrored the decreased OSM pathway activation score observed in vFB3 (Fig. S14B).

Prominent antigen presenting activities, were evident in MO^{VCAN}, MO^{CD16}, cDC1 and cDC2, also occurred in MP^{FOLR2}, akin to tumor-associated MP (54). Across antigen-presenting MP, *RBM20* LVs showed the highest presentation of antigens based on MHCII genes (Figs. S28B-C) and more abundant cDC2 compared to the other genotypes (Fig. S27). *PKP2* LVs

upregulated MP^{ISG} (Fig. S27) with interferon-stimulated genes (ISG) (55), perhaps contributing to inflammatory *PKP2* phenotypes (56).

Lymphoids

We classified 15 lymphoid cell states, including T- and natural killer (NK)-cell subsets, innate lymphoid cells (ILC), B-cells, plasma cells plus proliferating lymphoids (Figs. 4D, S29-32, Table S46). Our experimental design did not enrich for immune cells, and few (<40) genotype specific DEGs were identified (Fig. S29). Proliferating lymphoids were rare and abundance was unchanged in disease (Figs. S30, 32A-D, Table S47-52).

The cardiac complexity of CD4+ and CD8+T-cells included naive (CD4T^{naive}), activated (CD4T^{act}), regulatory (CD4T^{reg}) and cytotoxic (CD8T^{cytox}), transitional (CD8T^{trans}), terminal effector (CD8T^{te}) and effector memory (CD8T^{em}) cells (Fig. S31B) (57). We detected increased CD4T^{act} only within DCM samples (Figs. S32A-D). However, DEGs indicated lymphocyte activation (cytokines *IFNG*, *CCL3*, *CCL4* and signaling molecules *CBLB*, *FYN*, *TXNIP*), and maturation (cell surface receptors *CD69*, *CXCR4*), particularly in *PKP2* NK-, CD4+T, and CD8+T-cells (Fig. 4E).

CD4+helper T-cells are critical drivers in cardiomyopathy and myocarditis pathogenesis (58, 59). In *LMNA* CD4T^{act} we identified upregulation of *TBX21*, important for Th1 polarization. Conversely, Th2-polarization transcription factor *GATA3* was downregulated in PVneg (Fig. 4F).

Neuronal cells

Analysis of cardiac NCs was limited by rarity of this cell type (Figs. 5A, S33, Table S53-57). Across all NC states, DEGs indicated increased *NFATC2* in LVs with PVs and *PKP2* RVs, and genotype-selective enrichment of *LRRK2*, an activator of a neurotoxic cascade (60). Other upregulated DEGs function in proteoglycan synthesis for neuronal myelination and axon regeneration (*XYLT1* and *HS3ST4*), and a complement inhibitor (*SUSD4*) that impacts neural function and morphology (61, 62). Genotype-specific DEGs were highest in *PKP2*.

We identified previously described (4) and three new NC states (Figs. 5B-C, S34, S35) that were genotype and chamber-selective: NC1.1 in *LMNA* and *TTN* LVs; NC1.2 in *TTN* and *RBM20* LVs and in *LMNA*, *TTN*, and *PKP2* RVs. NC1.1 was distinguished by the highest upregulation of *NFATC2*. NC1.2 upregulated genes associated with electrocardiogram intervals (*SLC35F1* and *AJAPI*; Fig. 5D), *IGFBP5*, involved in neuronal apoptosis and autophagy, and the ion channel and heart rate regulator *KCNKI* (63–65). NC1.3 was enriched for the neuromodulator receptor *GALRI*, and phosphodiesterases *PDE10A* and *PDE3B* that participate in neuroprotection and signaling (66–68). Dysregulated expression of genes involved in stress-responses and electrophysiology may account for characteristic life-threatening arrhythmias in DCM and PVs in *PKP2* (1, 2).

Adipocytes

Similar to NCs, limited adipocytes were captured. We identified three adipocyte states previously found in controls: canonical AD1.0, expressing lipid metabolism genes; stromal AD2, expressing ECM genes; and immune AD3, expressing *OSMR* and cytokine responsive genes (Figs. 5E-F, S36, Table S60-64). While AD3 was not detected in disease, a fourth identified state, AD1.1 was almost exclusive to disease hearts (Figs. 5G, S37). Compositional analysis identified increased proportions of AD1.1 in *PKP2* LVs and RVs concurrent with decreased LV proportions of AD1.0. *LMNA* and *RBM20* RVs, unlike LVs, also increased proportions of AD1.1 (Figs. S38A-D).

DEGs between AD1.1 and AD1.0 revealed changes in fatty acid metabolism pathways (Fig. 5H). AD1.1 showed downregulation of *DGAT2*, encoding a triglyceride forming enzyme (69), and *G0S2* and *MGLL*, encoding lipolysis regulators (70). Conversely *ABHD5*, a positive lipolysis regulator (70, 71), *PDK4*, a kinase promoting the shift from glucose to fatty acid metabolism, and *CIDEA*, a regulator of adipose tissue energy expenditure, were upregulated. *PKP2* RVs which typically display fibrofatty replacement also showed an enrichment of Gene Ontology biological processes for apoptosis and cell death (Fig. 5I). These data implied genotype-specific state transitions or replacement of canonical adipocytes in DCM and ACM.

Differential expression of GWAS genes in cardiomyopathies

Genome-wide association studies (GWAS) have identified common genetic variants associated with DCM. We selected candidate genes from 15 previously identified DCM loci (Table S67) and examined expression across cell types and genotypes (Fig. S39). Overall, GWAS genes were more often DEGs in LV and RV than expected by chance in snRNAseq data (LV: OR=7.0, P=0.0007; RV: OR=6.1, P=0.0009, one-sided Fisher's exact test). Multiple genes showed cell type specific expressions, with the majority highly enriched in CM (*ALPK3*, *BAG3*, *FHOD3*, *FLNC*, *HSPB7*, *MLIP*, *SLC6A6*, *SMARCB1*, *SVIL* and *TTN*). Among these we observed both genotype- and chamber-specific expression differences. Heat shock protein *HSPB7* was reduced in *TTN* LVs and in *LMNA* and *PKP2* RVs. *SLC6A6*, a taurine and amino acid transporter with cardioprotective effects, was increased in both LV and RV across all genotypes except for *PKP2* and PVneg. *CDKN1A*, a cell cycle regulator and modulator of apoptosis (72) was increased in *LMNA* CMs from LVs but not RVs (72).

GWAS genes that were more broadly expressed across cell types included *MTSSI*, encoding a putative actin-cytoskeletal interactor. *MTSSI* showed highest and unchanged expression in myeloids and was widely increased in mural cells as well as in FBs in *LMNA*, *TTN*, and *PKP2* (Fig. S39), suggesting influences beyond direct effects on CM function (73, 74). *SLC39A8*, a lowly expressed cardiac solute carrier, was unchanged in CMs but increased in *LMNA* and *TTN* LV ECs. We suggest that cell-specific expression changes of GWAS genes may improve interpretation of their biologic effects.

Predicted and altered cell-cell interactions across genotypes

By examining the expression of genes encoding for receptors and ligands, we inferred intercellular signaling and communication (75). We initially quantified the probability of cell-cell interactions and compared signaling between cell states, and then aggregated information to produce cell-specific and across-all-cell-types data, for each genotype relative to controls. This sequential approach accounted for differential abundances of cell states.

We detected aberrant intercellular signaling across disease (Figs. 6A, S40), including upregulation of BMP, FN1, Collagen, EGF, IGF and TGF pathways that promote fibrosis. Signaling dependent on VEGF, NOTCH and ANGPT was also increased in disease, implying

vascular remodeling. Strikingly, genotype-selective increases in intercellular signaling pathways were also identified in LVs (Figs. 6B, S40A, B): EDN in *LMNA*, the proinflammatory IL6 in *TTN*, BAFF/LIGHT (denoting TNF signaling) in *RBM20*, pro-inflammatory CCL and TNF in *PKP2*, and the immune modulator BTLA in PVneg. Some of these intercellular signaling pathways were similarly dysregulated in RV, but chamber-specific changes were also observed (Figs. S40C, D, S41).

We also identified genotype-specific differences in the cells sending and receiving signals in disease pathways (Figs. 6C). For example, IGF signaling (Fig. S42), crucial in cell growth and CM hypertrophy, showed increased FB autocrine (highest in *PKP2*) and paracrine FB to CM signaling, paralleling findings in experimental models (76, 77). In addition, IGF signaling from myeloid cells to CMs only occurred in *TTN*, *PKP2* and PVneg, an interaction that might promote muscle repair (78).

The source of BMP signaling changed in a genotype-specific manner (Figs. 6C, S43). BMP signaling from MC to CM was increased in *TTN* LVs and RVs but was downregulated in PVneg and *LMNA* LVs and other RVs (Figs. S41, S43). Notably, BMP signaling in ECs originated solely from EC7, likely depending on *BMP6* upregulation (Figs. 3E, G). EDN signaling from EC7 to CM and MC was highly genotype-selective, occurring in *LMNA* LV and *PKP2* RV (Fig. S44).

NRG signaling (comprising *NRG1-3* and *ERBB* receptors) showed multifaceted changes. Disease LVs markedly attenuated autocrine NRG signaling in CMs, while EC and CM signaling was upregulated (highest in *LMNA*) in all genotypes except *RBM20* (Fig. 6C, S45). Additionally, NRG3-ERBB4 interactions identified in controls shifted in disease to NRG1-ERBB4 and NRG1-ERBB3 in a genotype-specific manner, consistent with changes in *NRG1/3* expression in EC7 (Figs. 3G, S46) (79). This predicted NRG/ERBB shift may provide compensatory responses to adverse remodeling in cardiomyopathies (48).

Graph attention networks recognized genotype-specific expression patterns

We applied machine learning approaches to snRNAseq data to further advance the recognition of cell and genotype-specific transcriptional patterns. Cell-specific neighborhood graphs showed more connectivities among single-nuclei transcriptomes from PVneg hearts and

hearts with PVs in the same gene, compared to PVs from different genes (Fig. S47). Subsequently, we generated a graph attention network (GAT) for multinomial classification of genotypes trained on four major informative LV cell types: CMs, FBs, ECs, and myeloids (Fig. S47A-B). The GAT predicted *LMNA*, *TTN*, *RBM20*, *PKP2*, and PVneg genotypes with high accuracy. Among LV samples, the genotype prediction accuracy differed by cell types: CMs: 0.93, FBs: 0.92, myeloids: 0.85, ECs: 0.79 (Figs. 6D, S48, Tables S69-70; corresponding RV data Fig. S47C). Aggregation of genotype predictions obtained from these four LV cell types strengthened the correct prediction of genotypes, resulting in a high confidence model (Fig. 6D). Of note, three (H10, H22 and H33) of the four lower prediction probabilities occurred in samples with both a primary and secondary PVs, assigned as such by prior genotype and clinical phenotype review (Table S1). Moreover, as this machine learning model independently confirmed a genotype- and cell type-specific transcriptional signature, we concluded that these snRNAseq datasets accurately described the molecular responses to PVs and unexplained causes of DCM and ACM.

Discussion

Our analyses of snRNAseq of LV and RV samples illuminated the cell types and states, molecular signals, and predicted intercellular communications that characterized DCM and ACM. In comparison to control hearts, we identified differences at multiple levels, including changes in the proportions of cell types and states, additional cell states, and differential gene expression, substantially expanding earlier insights achieved by bulk tissue analyses. Across all genotypes, disease hearts demonstrated some common dissimilarities from control hearts, often with graded differences between LVs and RVs. Despite studying hearts from patients with advanced disease who received diverse therapies, congruent transcriptional signatures emerged for different PVs within the same gene and varied between genotypes.

The differences between genotype groups and controls reflected differences in mean expression and not differences in variance. This was true for each genotype group including PVneg. Transcriptional signatures were complex, diversified both by the proportions of canonical

and stressed cell states and by differentially expressed genes within the same states. While interrogation of these datasets provides ongoing opportunities for discovery, our findings provided substantial evidence that genotype influenced pathological remodeling of the heart. These results upend a prevalent dogma that HF results from a common final pathway and can guide the future development of therapies with selective targets to enhance personalized medicine.

Despite anatomical and histopathological differences between DCM and ACM, we identified shared changes in the cellular composition of ventricular tissues, albeit with DCM LV features largely mirrored in ACM RVs. Cardiomyopathies were depleted in CMs while EC and immune cell populations were increased. FBs did not expand, but increased states that augmented ECM gene expression and collagen deposition. Based on these changes and cytokine profiles (TGF β activation, increased IGF signaling, decreased *CCL2* expression; Figs. 2H-I, 6C), we predicted cell-cell interactions and key molecules that are appropriate for mechanistic studies to causally link differential expression with adverse cardiac remodeling.

Disease CMs exhibited loss of the canonical state vCM1.0, and the emergence of genotype-enriched cell states with DEGs. Many of these responses are associated with stress-induced contractile, metabolic, and electrophysiologic properties that are prominent clinical manifestations of some genotypes. For example, attenuated expression of *SMYDI*, a critical organizer of sarcomere structure, epigenetic and metabolic remodeling, occurred only in CMs with PVs, and was unaltered in PVneg samples. With its global impact on myocardial function, dysregulation of *SMYDI* might contribute to earlier presentation and poorer outcomes of cardiomyopathy patients with, versus without, PVs (80). *LMNA* CMs had the greatest expansion of vCM1.2, enriched for genes encoding Ca²⁺ regulators and molecules with electrophysiologic functions, while *RMB20* and *LMNA* genotypes had the highest expression of *MYLA*, a sarcomere protein associated with atrial fibrillation. These data suggested molecular mechanisms whereby particular genotypes convey increased risks for arrhythmias and sudden cardiac death in patients.

Shifts in FB states explained the paradoxically increased fibrosis in cardiomyopathies, without expansion of overall FB populations. DCM LVs and ACM RVs showed increased proportions of vFB2, enriched for genes that modulate ECM composition, turnover, stiffness and

fibrotic scarring (81) and reciprocally decreased proportions of vFB3 that express transcripts suppressing fibrosis. Notably, fibrogenic genes within vFB2 were highly expressed in *RBM20*, a genotype within our cohort with the poorest ventricular function and youngest age for HF diagnosis and cardiac transplantation. Strategies to manipulate proteins encoded by these genes may attenuate the prominent myocardial fibrosis that characterizes cardiomyopathies.

Unexpectedly, mural cells (PCs, SMCs) showed no increase compared to ECs across cardiomyopathies. DEG analysis suggested that these cells promoted vascular remodeling and dysfunction. PCs diminished *PDGFRB* expression and showed aberrant NOTCH signaling in vascular beds, while genotype selective DEGs in SMCs upregulated contractile genes, augmenting fiber formation. Together these molecular signals may contribute to microvascular dysfunction that occurs in cardiomyopathy patients (82) and adversely influences ventricular performance.

Among EC, EC7 demarcated the endocardium and had the most DEGs in disease compared to control. Little is known about this myocardial layer in HF pathogenesis. The endocardium forms via dynamic regulation of NOTCH, neuregulin (83) and BMP (84) signals. Pediatric heart diseases can exhibit pathological expansion of the endocardium (denoted endocardial fibroelastosis) which diminishes cardiac performance and is associated with progression to HF (84). Our data suggested similar dysregulation of these molecular pathways in adult-onset cardiomyopathies with increased *BMP6* and *NRG1* in EC7 and decreased *INHBA* (53). These signals may cause pathological changes in endocardium in DCM and ACM hearts and contribute to myocardial dysfunction.

Diseased hearts increased myeloid cells. Expansion of immune cell populations might arise from recruitment of circulating cells or proliferation of resident cells. In our samples proliferating myeloid cells decreased, as previously observed in other DCM studies (85). Surprisingly, myeloid recruitment via the CCR2/CCL2 axis, primarily mediated via vFB3, was decreased in all samples, with particularly dysregulated fibroblast-to-macrophage interactions in *TTN*. Although distinguishing between proliferation versus recruitment late in disease was problematic, previous studies indicate peak cytokine expression precedes the emergence of HF (86, 87). Analyses of earlier time points during disease progression will be important to discern these key signals.

To confirm and expand the conclusion that genotype-specific signals meaningfully contributed to disease pathogenesis, we employed machine learning strategies. Using GAT to classify patients' genotypes from each cell type, we found that CMs, FBs, ECs, and myeloid cells provided the highest and most discriminatory information. Harnessing LV and RV data from these cell types, we independently predicted the established genotype of each patient with high accuracy. Moreover, among the four samples with the lowest genotype predictive probability, three samples carried two PVs, indicating that the model detected subtle transcriptional differences with additional influences.

While expanding machine learning models to much larger datasets will undoubtedly improve accuracy, these early analyses supported the conclusion that PVs in different genes evoked cell type and state-specific responses that altered inter-cellular communications and promoted distinct disease pathways. We recognize that pathways may converge, but even in advanced disease, our data indicated that genotypes promoted specific transcriptional signals that likely contributed to distinct as well as common manifestations of genetic cardiomyopathies.

Future studies are needed to comprehensively define the molecular pathophysiology of cardiomyopathies and HF, including assessments of age, sex, and ancestral influences, other DCM and ACM genotypes, additional cardiac regions, and longitudinal analyses to identify initiating and secondary processes. We also expect that the deployment of strategies that upsample conduction system and other rare cell types, and incorporation of techniques to characterize the epigenome, proteome, and spatial relationships between cell types, states, and gene expression will also be highly informative. To promote these initiatives, we freely provide all datasets and an interactive platform (<https://cellxgene.cziscience.com/collections/e75342a8-0f3b-4ec5-8ee1-245a23e0f7cb>) with cell type and state annotations. We expect that these resources will advance mechanistic studies to improve treatments of cardiomyopathies and enable HF prevention strategies.

Materials and methods

Detailed information on human subject studies, experimental methods, data access, codes, algorithms, and computational programs used in this manuscript is provided in the Supplementary Materials (89).

Human studies were performed using protocols that were reviewed and approved by the ethics boards of participating institutions. DCM and ACM ventricular samples were collected from genotyped patients undergoing mechanical support (n=15) or heart transplantation (n=31) and from deceased donors with non-failing hearts as previously described (4). Nuclei from full-thickness LV and RV regions were isolated and processed for snRNAseq as described (4). Data were mapped to the human genome (GRCh38), processed to remove doublets and identify nuclei that met high quality standards, and harmonized to remove batch effects (105). Manifolds were constructed using Uniform Manifold Approximation and Projections (UMAPs) for all and individual cell types.

Differential abundance analyses of cell types and states were performed using centered log ratio transformation including a linear model. Differential gene expression between disease and control tissues were deduced using a pseudobulk approach and EdgeR (109, 110). Comparative analyses assessed cell type and cell state abundances and differential gene expression between disease samples and controls and between genotypes. Selected genes with differential expression were validated using single molecule fluorescent *in situ* hybridization or quantitative immunohistochemistry.

We investigated cell-cell communication using CellChat (75). The expression of genes previously identified through genome wide-association studies of DCM was assessed in diseased and control tissues. We interrogated transcriptional datasets with machine learning tools to generate cell type features that distinguished PVs within the same gene from PVs within different genes and used these data to generate a graph attention network (GAT). The accuracy for GAT analyses of randomly selected patient data to assign the correct, clinically assigned genotype was assessed.

References and Notes

1. E. M. McNally, L. Mestroni, Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. *Circ. Res.* **121**, 731–748 (2017).
2. K. M. Austin, M. A. Trembley, S. F. Chandler, S. P. Sanders, J. E. Saffitz, D. J. Abrams, W. T. Pu, Molecular mechanisms of arrhythmogenic cardiomyopathy. *Nature Reviews Cardiology.* **16** (2019), pp. 519–537.
3. A. L. Bui, T. B. Horwich, G. C. Fonarow, Epidemiology and risk profile of heart failure. *Nat. Rev. Cardiol.* **8**, 30–41 (2011).
4. M. Litviňuková, C. Talavera-López, H. Maatz, D. Reichart, C. L. Worth, E. L. Lindberg, M. Kanda, K. Polanski, M. Heinig, M. Lee, E. R. Nadelmann, K. Roberts, L. Tuck, E. S. Fasouli, D. M. DeLaughter, B. McDonough, H. Wakimoto, J. M. Gorham, S. Samari, K. T. Mahbubani, K. Saeb-Parsy, G. Patone, J. J. Boyle, H. Zhang, H. Zhang, A. Viveiros, G. Y. Oudit, O. A. Bayraktar, J. G. Seidman, C. E. Seidman, M. Nosedá, N. Hubner, S. A. Teichmann, Cells of the adult human heart. *Nature.* **588**, 466–472 (2020).
5. J. S. Warren, C. M. Tracy, M. R. Miller, A. Makaju, M. W. Szulik, S.-I. Oka, T. N. Yuzyuk, J. E. Cox, A. Kumar, B. K. Lozier, L. Wang, J. G. Llana, A. D. Sabry, K. M. Cawley, D. W. Barton, Y. H. Han, S. Boudina, O. Fiehn, H. O. Tucker, A. V. Zaitsev, S. Franklin, Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E7871–E7880 (2018).
6. S. Franklin, T. Kimball, T. L. Rasmussen, M. Rosa-Garrido, H. Chen, T. Tran, M. R. Miller, R. Gray, S. Jiang, S. Ren, Y. Wang, H. O. Tucker, T. M. Vondriska, The chromatin-binding protein Smyd1 restricts adult mammalian heart growth. *Am. J. Physiol. Heart Circ. Physiol.* **311**, H1234–H1247 (2016).
7. S. F. Steinberg, Beta-Adrenergic Receptor Regulation Revisited. *Circ. Res.* **123**, 1199–1201 (2018).
8. M. R. Bristow, Mechanism of Action of Beta-Blocking Agents in Heart Failure. *The American Journal of Cardiology.* **80** (1997), p. 26L–40L.
9. Y. Hasumi, M. Baba, H. Hasumi, Y. Huang, M. Lang, R. Reindorf, H.-B. Oh, S. Sciarretta, K. Nagashima, D. C. Haines, M. D. Schneider, R. S. Adelstein, L. S. Schmidt, J. Sadoshima, W. Marston Linehan, Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. *Hum. Mol. Genet.* **23**, 5706–5719 (2014).
10. H. Hasumi, M. Baba, Y. Hasumi, M. Lang, Y. Huang, H. F. Oh, M. Matsuo, M. J. Merino, M. Yao, Y. Ito, M. Furuya, Y. Iribe, T. Kodama, E. Southon, L. Tessarollo, K. Nagashima, D. C. Haines, W. M. Linehan, L. S. Schmidt, Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E1624–31 (2015).
11. K. Shen, K. B. Rogala, H.-T. Chou, R. K. Huang, Z. Yu, D. M. Sabatini, Cryo-EM Structure

- of the Human FLCN-FNIP2-Rag-Ragulator Complex. *Cell*. **179**, 1319–1329.e8 (2019).
12. M. Mejias, J. Gallego, S. Naranjo-Suarez, M. Ramirez, N. Pell, A. Manzano, C. Suñer, R. Bartrons, R. Mendez, M. Fernandez, CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. *Gastroenterology*. **159**, 273–288 (2020).
 13. R. Ajima, H. Akazawa, M. Kodama, F. Takeshita, A. Otsuka, T. Kohno, I. Komuro, T. Ochiya, J. Yokota, Deficiency of Myo18B in mice results in embryonic lethality with cardiac myofibrillar aberrations. *Genes Cells*. **13**, 987–999 (2008).
 14. M. Hueso, L. De Ramon, E. Navarro, E. Ripoll, J. M. Cruzado, J. M. Grinyo, J. Torras, Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF- κ B/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis. *Atherosclerosis*. **255**, 80–89 (2016).
 15. S.-Y. Kim, S. Yasuda, H. Tanaka, K. Yamagata, H. Kim, Non-clustered protocadherin. *Cell Adh. Migr*. **5**, 97–105 (2011).
 16. Y. Li, C. D. Merkel, X. Zeng, J. A. Heier, P. S. Cantrell, M. Sun, D. B. Stolz, S. C. Watkins, N. A. Yates, A. V. Kwiatkowski, The N-cadherin interactome in primary cardiomyocytes as defined using quantitative proximity proteomics. *J. Cell Sci*. **132** (2019), doi:10.1242/jcs.221606.
 17. Y. Wang, M. Kerrisk Campbell, I. Tom, O. Foreman, J. E. Hanson, M. Sheng, PCDH7 interacts with GluN1 and regulates dendritic spine morphology and synaptic function. *Sci. Rep.* **10**, 10951 (2020).
 18. P. D. Swaminathan, A. Purohit, T. J. Hund, M. E. Anderson, Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. *Circ. Res.* **110**, 1661–1677 (2012).
 19. L. A. Swayne, N. P. Murphy, S. Asuri, L. Chen, X. Xu, S. McIntosh, C. Wang, P. J. Lancione, J. D. Roberts, C. Kerr, S. Sanatani, E. Sherwin, C. F. Kline, M. Zhang, P. J. Mohler, L. T. Arbour, Novel Variant in the Membrane-Binding Domain Is Associated With Ankyrin-B Syndrome and Structural Heart Disease in a First Nations Population With a High Rate of Long QT Syndrome. *Circ. Cardiovasc. Genet.* **10** (2017), doi:10.1161/CIRCGENETICS.116.001537.
 20. H. D. Devalla, R. Gélinas, E. H. Aburawi, A. Beqqali, P. Goyette, C. Freund, M.-A. Chaix, R. Tadros, H. Jiang, A. Le Béchech, J. J. Monshouwer-Kloots, T. Zwetsloot, G. Kosmidis, F. Latour, A. Alikashani, M. Hoekstra, J. Schlaepfer, C. L. Mummery, B. Stevenson, Z. Kutalik, A. A. de Vries, L. Rivard, A. A. Wilde, M. Talajic, A. O. Verkerk, L. Al-Gazali, J. D. Rioux, Z. A. Bhuiyan, R. Passier, TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT. *EMBO Mol. Med.* **8**, 1390–1408 (2016).
 21. V. Gaussin, G. E. Morley, L. Cox, A. Zwijsen, K. M. Vance, L. Emile, Y. Tian, J. Liu, C. Hong, D. Myers, S. J. Conway, C. Depre, Y. Mishina, R. R. Behringer, M. C. Hanks, M. D.

- Schneider, D. Huylebroeck, G. I. Fishman, J. B. E. Burch, S. F. Vatner, Alk3/Bmpr1a receptor is required for development of the atrioventricular canal into valves and annulus fibrosus. *Circ. Res.* **97**, 219–226 (2005).
22. N. W. Morrell, D. B. Bloch, P. ten Dijke, M.-J. T. H. Goumans, A. Hata, J. Smith, P. B. Yu, K. D. Bloch, Targeting BMP signalling in cardiovascular disease and anaemia. *Nat. Rev. Cardiol.* **13**, 106–120 (2016).
23. J. Filmus, M. Capurro, The role of glypicans in Hedgehog signaling. *Matrix Biol.* **35**, 248–252 (2014).
24. M. L. Schmitz, M. S. Shaban, B. V. Albert, A. Gökçen, M. Kracht, The Crosstalk of Endoplasmic Reticulum (ER) Stress Pathways with NF-κB: Complex Mechanisms Relevant for Cancer, Inflammation and Infection. *Biomedicines.* **6** (2018), doi:10.3390/biomedicines6020058.
25. M. Wilhelm, N. V. Kukekov, T. L. Schmit, K. V. Biagas, A. A. Sproul, S. Gire, M. E. Maes, Z. Xu, L. A. Greene, Sh3rf2/POSHER protein promotes cell survival by ring-mediated proteasomal degradation of the c-Jun N-terminal kinase scaffold POSH (Plenty of SH3s) protein. *J. Biol. Chem.* **287**, 2247–2256 (2012).
26. R. Eckenstaler, J. Sandori, M. Gekle, R. A. Benndorf, Angiotensin II receptor type 1 – An update on structure, expression and pathology. *Biochem. Pharmacol.* **192**, 114673 (2021).
27. H. Itabashi, C. Maesawa, H. Oikawa, K. Kotani, E. Sakurai, K. Kato, H. Komatsu, H. Nitta, H. Kawamura, G. Wakabayashi, T. Masuda, Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. *Hepatol. Res.* **38**, 601–613 (2008).
28. C. F. Baicu, Y. Zhang, A. O. Van Laer, L. Renaud, M. R. Zile, A. D. Bradshaw, Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. *Am. J. Physiol. Heart Circ. Physiol.* **303**, H234–40 (2012).
29. K. J. Travaglini, A. N. Nabhan, L. Penland, R. Sinha, A. Gillich, R. V. Sit, S. Chang, S. D. Conley, Y. Mori, J. Seita, G. J. Berry, J. B. Shrager, R. J. Metzger, C. S. Kuo, N. Neff, I. L. Weissman, S. R. Quake, M. A. Krasnow, A molecular cell atlas of the human lung from single-cell RNA sequencing. *Nature.* **587**, 619–625 (2020).
30. S. Schafer, S. Viswanathan, A. A. Widjaja, W.-W. Lim, A. Moreno-Moral, D. M. DeLaughter, B. Ng, G. Patone, K. Chow, E. Khin, J. Tan, S. P. Chothani, L. Ye, O. J. L. Rackham, N. S. J. Ko, N. E. Sahib, C. J. Pua, N. T. G. Zhen, C. Xie, M. Wang, H. Maatz, S. Lim, K. Saar, S. Blachut, E. Petretto, S. Schmidt, T. Putoczki, N. Guimarães-Camboa, H. Wakimoto, S. van Heesch, K. Sigmundsson, S. L. Lim, J. L. Soon, V. T. T. Chao, Y. L. Chua, T. E. Tan, S. M. Evans, Y. J. Loh, M. H. Jamal, K. K. Ong, K. C. Chua, B.-H. Ong, M. J. Chakaramakkil, J. G. Seidman, C. E. Seidman, N. Hubner, K. Y. K. Sin, S. A. Cook, IL-11 is a crucial determinant of cardiovascular fibrosis. *Nature.* **552**, 110–115 (2017).
31. S. Nandadasa, C. M. Nelson, S. S. Apte, ADAMTS9-Mediated Extracellular Matrix

- Dynamics Regulates Umbilical Cord Vascular Smooth Muscle Differentiation and Rotation. *Cell Reports*. **11** (2015), pp. 1519–1528.
32. B.-H. Koo, D. M. Coe, L. J. Dixon, R. P. T. Somerville, C. M. Nelson, L. W. Wang, M. E. Young, D. J. Lindner, S. S. Apte, ADAMTS9 Is a Cell-Autonomously Acting, Anti-Angiogenic Metalloprotease Expressed by Microvascular Endothelial Cells. *The American Journal of Pathology*. **176** (2010), pp. 1494–1504.
 33. T. Nadeem, W. Bogue, B. Bigit, H. Cuervo, Deficiency of Notch signaling in pericytes results in arteriovenous malformations. *JCI Insight*. **5** (2020), doi:10.1172/jci.insight.125940.
 34. P. U. Magnusson, C. Looman, A. Ahgren, Y. Wu, L. Claesson-Welsh, R. L. Heuchel, Platelet-derived growth factor receptor-beta constitutive activity promotes angiogenesis in vivo and in vitro. *Arterioscler. Thromb. Vasc. Biol.* **27** (2007), doi:10.1161/01.ATV.0000282198.60701.94.
 35. S. Jin, E. M. Hansson, S. Tikka, F. Lanner, C. Sahlgren, F. Farnebo, M. Baumann, H. Kalimo, U. Lendahl, Notch Signaling Regulates Platelet-Derived Growth Factor Receptor- β Expression in Vascular Smooth Muscle Cells. *Circulation Research*. **102** (2008), pp. 1483–1491.
 36. V. Domenga, P. Fardoux, P. Lacombe, M. Monet, J. Maciazek, L. T. Krebs, B. Klonjowski, E. Berrou, M. Mericskay, Z. Li, E. Tournier-Lasserre, T. Gridley, A. Joutel, Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. *Genes Dev*. **18** (2004), doi:10.1101/gad.308904.
 37. A. H. Campos, W. Wang, M. J. Pollman, G. H. Gibbons, Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation. *Circ. Res.* **91**, 999–1006 (2002).
 38. I. Marek, T. Lichtneger, N. Cordasic, K. F. Hilgers, G. Volkert, F. Fahlbusch, W. Rascher, A. Hartner, C. Menendez-Castro, Alpha8 Integrin (Itga8) Signalling Attenuates Chronic Renal Interstitial Fibrosis by Reducing Fibroblast Activation, Not by Interfering with Regulation of Cell Turnover. *PLoS One*. **11**, e0150471 (2016).
 39. C. F. Hung, C. L. Wilson, Y.-H. Chow, L. M. Schnapp, Role of integrin alpha8 in murine model of lung fibrosis. *PLOS ONE*. **13** (2018), p. e0197937.
 40. J. J. Connelly, O. A. Cherepanova, J. F. Doss, T. Karaoli, T. S. Lillard, C. A. Markunas, S. Nelson, T. Wang, P. D. Ellis, C. F. Langford, C. Haynes, D. M. Seo, P. J. Goldschmidt-Clermont, S. H. Shah, W. E. Kraus, E. R. Hauser, S. G. Gregory, Epigenetic regulation of COL15A1 in smooth muscle cell replicative aging and atherosclerosis. *Hum. Mol. Genet.* **22**, 5107 (2013).
 41. L. Gong, S. Wang, L. Shen, C. Liu, M. Shenouda, B. Li, X. Liu, J. A. Shaw, A. L. Wineman, Y. Yang, D. Xiong, A. Eichmann, S. M. Evans, S. J. Weiss, M.-S. Si, SLIT3 deficiency attenuates pressure overload-induced cardiac fibrosis and remodeling. *JCI Insight*. **5** (2020),

doi:10.1172/jci.insight.136852.

42. R. Sewduth, M. M. Santoro, “Decoding” Angiogenesis: New Facets Controlling Endothelial Cell Behavior. *Front. Physiol.* **7**, 306 (2016).
43. S. L. House, A. M. Castro, T. S. Lupu, C. Weinheimer, C. Smith, A. Kovacs, D. M. Ornitz, Endothelial fibroblast growth factor receptor signaling is required for vascular remodeling following cardiac ischemia-reperfusion injury. *Am. J. Physiol. Heart Circ. Physiol.* **310**, H559–71 (2016).
44. X.-B. Cui, S.-Y. Chen, Response Gene to Complement 32 in Vascular Diseases. *Front Cardiovasc Med.* **5**, 128 (2018).
45. Y. Xiao, M. C. Hill, M. Zhang, T. J. Martin, Y. Morikawa, S. Wang, A. R. Moise, J. D. Wythe, J. F. Martin, Hippo Signaling Plays an Essential Role in Cell State Transitions during Cardiac Fibroblast Development. *Dev. Cell.* **45**, 153–169.e6 (2018).
46. J. Tang, H. Zhang, L. He, X. Huang, Y. Li, W. Pu, W. Yu, L. Zhang, D. Cai, K. O. Lui, B. Zhou, Genetic Fate Mapping Defines the Vascular Potential of Endocardial Cells in the Adult Heart. *Circ. Res.* **122**, 984–993 (2018).
47. R. A. Norris, R. A. Moreno-Rodriguez, Y. Sugi, S. Hoffman, J. Amos, M. M. Hart, J. D. Potts, R. L. Goodwin, R. R. Markwald, Periostin regulates atrioventricular valve maturation. *Dev. Biol.* **316**, 200–213 (2008).
48. G. W. De Keulenaer, E. Feyen, L. Dugaucquier, H. Shakeri, A. Shchendrygina, Y. N. Belenkov, M. Brink, Z. Vermeulen, V. F. M. Segers, Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure. *Circ. Heart Fail.* **12**, e006288 (2019).
49. X.-S. Zhao, W. Pan, R. Bekerredjian, R. V. Shohet, Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. *Circulation.* **114**, 830–837 (2006).
50. C. K. Hathaway, R. Grant, J. R. Hagaman, S. Hiller, F. Li, L. Xu, A. S. Chang, V. J. Madden, C. R. Bagnell, M. Rojas, H.-S. Kim, B. Wu, B. Zhou, O. Smithies, M. Kakoki, Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 5141–5146 (2015).
51. R. Y. Kim, E. J. Robertson, M. J. Solloway, Bmp6 and Bmp7 are required for cushion formation and septation in the developing mouse heart. *Dev. Biol.* **235**, 449–466 (2001).
52. Y. Fang, K. S. Lai, P. She, J. Sun, W. Tao, T. P. Zhong, Tbx20 Induction Promotes Zebrafish Heart Regeneration by Inducing Cardiomyocyte Dedifferentiation and Endocardial Expansion. *Front. Cell Dev. Biol.* **0** (2020), doi:10.3389/fcell.2020.00738.
53. A. C. Y. Chang, Y. Fu, V. C. Garside, K. Niessen, L. Chang, M. Fuller, A. Setiadi, J. Smrz, A. Kyle, A. Minchinton, M. Marra, P. A. Hoodless, A. Karsan, Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine

- activation of soluble guanylyl cyclase. *Dev. Cell.* **21**, 288–300 (2011).
54. A. Puig-Kröger, E. Sierra-Filardi, A. Domínguez-Soto, R. Samaniego, M. T. Corcuera, F. Gómez-Aguado, M. Ratnam, P. Sánchez-Mateos, A. L. Corbí, Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. *Cancer Res.* **69**, 9395–9403 (2009).
 55. S. A. Dick, J. A. Macklin, S. Nejat, A. Momen, X. Clemente-Casares, M. G. Althagafi, J. Chen, C. Kantores, S. Hosseinzadeh, L. Aronoff, A. Wong, R. Zaman, I. Barbu, R. Besla, K. J. Lavine, B. Razani, F. Ginhoux, M. Husain, M. I. Cybulsky, C. S. Robbins, S. Epelman, Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. *Nat. Immunol.* **20**, 29–39 (2019).
 56. M. Pérez-Hernández, G. M. Marrón-Liñares, F. Schlamp, A. Heguy, C. J. M. van Opbergen, V. Mezzano, M. Zhang, F.-X. Liang, M. Cerrone, M. Delmar, Transcriptomic Coupling of PKP2 With Inflammatory and Immune Pathways Endogenous to Adult Cardiac Myocytes. *Front. Physiol.* **0** (2021), doi:10.3389/fphys.2020.623190.
 57. A. M. van der Leun, D. S. Thommen, T. N. Schumacher, CD8 T cell states in human cancer: insights from single-cell analysis. *Nat. Rev. Cancer.* **20**, 218–232 (2020).
 58. J. G. Barin, D. Čiháková, Control of inflammatory heart disease by CD4+ T cells. *Ann. N. Y. Acad. Sci.* **1285**, 80–96 (2013).
 59. D. Vdovenko, U. Eriksson, Regulatory Role of CD4 T Cells in Myocarditis. *J Immunol Res.* **2018**, 4396351 (2018).
 60. C. Kim, A. Beilina, N. Smith, Y. Li, M. Kim, R. Kumaran, A. Kaganovich, A. Mamais, A. Adame, M. Iba, S. Kwon, W.-J. Lee, S.-J. Shin, R. A. Rissman, S. You, S.-J. Lee, A. B. Singleton, M. R. Cookson, E. Masliah, LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. *Sci. Transl. Med.* **12** (2020), doi:10.1126/scitranslmed.aay0399.
 61. N. B. Schwartz, M. S. Domowicz, Proteoglycans in brain development and pathogenesis. *FEBS Lett.* **592**, 3791–3805 (2018).
 62. H. Zhu, L. E. Meissner, C. Byrnes, G. Tuymetova, C. J. Tiffit, R. L. Proia, The Complement Regulator *Susd4* Influences Nervous-System Function and Neuronal Morphology in Mice. *iScience.* **23**, 100957 (2020).
 63. R. Méndez-Giráldez, S. M. Gogarten, J. E. Below, J. Yao, A. A. Seyerle, H. M. Highland, C. Kooperberg, E. Z. Soliman, J. I. Rotter, K. F. Kerr, K. K. Ryckman, K. D. Taylor, L. E. Petty, S. J. Shah, M. P. Conomos, N. Sotoodehnia, S. Cheng, S. R. Heckbert, T. Sofer, X. Guo, E. A. Whitsel, H. J. Lin, C. L. Hanis, C. C. Laurie, C. L. Avery, GWAS of the electrocardiographic QT interval in Hispanics/Latinos generalizes previously identified loci and identifies population-specific signals. *Sci. Rep.* **7**, 17075 (2017).
 64. A. H. Christensen, F. C. Chatelain, I. G. Huttner, M. S. Olesen, M. Soka, S. Feliciangeli, C.

- Horvat, C. F. Santiago, J. I. Vandenberg, N. Schmitt, S.-P. Olesen, F. Lesage, D. Fatkin, The two-pore domain potassium channel, TWIK-1, has a role in the regulation of heart rate and atrial size. *J. Mol. Cell. Cardiol.* **97**, 24–35 (2016).
65. X. Xu, E. Huang, B. Luo, D. Cai, X. Zhao, Q. Luo, Y. Jin, L. Chen, Q. Wang, C. Liu, Z. Lin, W. Xie, H. Wang, Methamphetamine exposure triggers apoptosis and autophagy in neuronal cells by activating the C/EBP β -related signaling pathway. *The FASEB Journal.* **32** (2018), pp. 6737–6759.
66. P. E. Schauwecker, Galanin receptor 1 deletion exacerbates hippocampal neuronal loss after systemic kainate administration in mice. *PLoS One.* **5**, e15657 (2010).
67. V. Beaumont, S. Zhong, H. Lin, W. Xu, A. Bradaia, E. Steidl, M. Gleyzes, K. Wadel, B. Buisson, F. E. Padovan-Neto, S. Chakroborty, K. M. Ward, J. F. Harms, J. Beltran, M. Kwan, A. Ghavami, J. Häggkvist, M. Tóth, C. Halldin, A. Varrone, C. Schaab, J. N. Dybowski, S. Elschenbroich, K. Lehtimäki, T. Heikkinen, L. Park, J. Rosinski, L. Mrzljak, D. Lavery, A. R. West, C. J. Schmidt, M. M. Zaleska, I. Munoz-Sanjuan, Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington’s Disease Models. *Neuron.* **92**, 1220–1237 (2016).
68. Y. Mitome-Mishima, N. Miyamoto, R. Tanaka, H. Oishi, H. Arai, N. Hattori, T. Urabe, Differences in phosphodiesterase 3A and 3B expression after ischemic insult. *Neurosci. Res.* **75**, 340–348 (2013).
69. C. Chitraju, T. C. Walther, R. V. Farese Jr, The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes. *J. Lipid Res.* **60**, 1112–1120 (2019).
70. M. Schweiger, M. Paar, C. Eder, J. Brandis, E. Moser, G. Gorkiewicz, S. Grond, F. P. W. Radner, I. Cerk, I. Cornaciu, M. Oberer, S. Kersten, R. Zechner, R. Zimmermann, A. Lass, G0/G1 switch gene-2 regulates human adipocyte lipolysis by affecting activity and localization of adipose triglyceride lipase. *J. Lipid Res.* **53**, 2307–2317 (2012).
71. M. A. Sanders, H. Zhang, L. Mladenovic, Y. Y. Tseng, J. G. Granneman, Molecular Basis of ABHD5 Lipolysis Activation. *Sci. Rep.* **7**, 42589 (2017).
72. K. Onoue, H. Wakimoto, J. Jiang, M. Parfenov, S. DePalma, D. Conner, J. Gorham, D. McKean, J. G. Seidman, C. E. Seidman, Y. Saito, Cardiomyocyte Proliferative Capacity Is Restricted in Mice With Mutation. *Front Cardiovasc Med.* **8**, 639148 (2021).
73. M. P. Morley, X. Wang, R. Hu, J. Brandimarto, N. R. Tucker, J. F. Felix, N. L. Smith, P. van der Harst, P. T. Ellinor, K. B. Margulies, K. Musunuru, T. P. Cappola, Cardioprotective Effects of MTSS1 Enhancer Variants. *Circulation.* **139**, 2073–2076 (2019).
74. H. V. Meyer, T. J. W. Dawes, M. Serrani, W. Bai, P. Tokarczuk, J. Cai, A. de Marvao, A. Henry, R. T. Lumbers, J. Gierten, T. Thumberger, J. Wittbrodt, J. S. Ware, D. Rueckert, P. M. Matthews, S. K. Prasad, M. L. Costantino, S. A. Cook, E. Birney, D. P. O’Regan, Genetic and functional insights into the fractal structure of the heart. *Nature.* **584**, 589–594 (2020).

75. S. Jin, C. F. Guerrero-Juarez, L. Zhang, I. Chang, R. Ramos, C.-H. Kuan, P. Myung, M. V. Plikus, Q. Nie, Inference and analysis of cell-cell communication using CellChat. *Nat. Commun.* **12**, 1088 (2021).
76. N. Takeda, I. Manabe, Y. Uchino, K. Eguchi, S. Matsumoto, S. Nishimura, T. Shindo, M. Sano, K. Otsu, P. Snider, S. J. Conway, R. Nagai, Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. *J. Clin. Invest.* **120**, 254–265 (2010).
77. T. Horio, T. Maki, I. Kishimoto, T. Tokudome, H. Okumura, F. Yoshihara, S.-I. Suga, S. Takeo, Y. Kawano, K. Kangawa, Production and autocrine/paracrine effects of endogenous insulin-like growth factor-1 in rat cardiac fibroblasts. *Regul. Pept.* **124**, 65–72 (2005).
78. J. Tonkin, L. Temmerman, R. D. Sampson, E. Gallego-Colon, L. Barberi, D. Bilbao, M. D. Schneider, A. Musarò, N. Rosenthal, Monocyte/Macrophage-derived IGF-1 Orchestrates Murine Skeletal Muscle Regeneration and Modulates Autocrine Polarization. *Mol. Ther.* **23**, 1189–1200 (2015).
79. O. Odiete, M. F. Hill, D. B. Sawyer, Neuregulin in cardiovascular development and disease. *Circ. Res.* **111**, 1376–1385 (2012).
80. L. Escobar-Lopez, J. P. Ochoa, J. G. Mirelis, M. Á. Espinosa, M. Navarro, M. Gallego-Delgado, R. Barriales-Villa, A. Robles-Mezcua, M. T. Basurte-Elorz, L. Gutiérrez García-Moreno, V. Climent, J. Jiménez-Jaimez, M. V. Mogollón-Jiménez, J. Lopez, M. L. Peña-Peña, A. García-Álvarez, M. Brion, T. Ripoll-Vera, J. Palomino-Doza, C. Tirón, U. Idiazabal, M. N. Brögger, S. García-Hernández, M. A. Restrepo-Córdoba, E. Gonzalez-Lopez, I. Méndez, M. Sabater, E. Villacorta, J. M. Larrañaga-Moreira, A. Abecia, A. I. Fernández, J. M. García-Pinilla, J. F. Rodríguez-Palomares, J. R. Gimeno-Blanes, A. Bayes-Genis, E. Lara-Pezzi, F. Domínguez, P. Garcia-Pavia, Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. *J. Am. Coll. Cardiol.* **78**, 1682–1699 (2021).
81. P. Kong, P. Christia, N. G. Frangogiannis, The pathogenesis of cardiac fibrosis. *Cell. Mol. Life Sci.* **71**, 549–574 (2014).
82. A. Gulati, T. F. Ismail, A. Ali, L.-Y. Hsu, C. Gonçalves, N. A. Ismail, K. Krishnathasan, N. Davendralingam, P. Ferreira, B. P. Halliday, D. A. Jones, R. Wage, S. Newsome, P. Gatehouse, D. Firmin, A. Jabbour, R. G. Assomull, A. Mathur, D. J. Pennell, A. E. Arai, S. K. Prasad, Microvascular Dysfunction in Dilated Cardiomyopathy: A Quantitative Stress Perfusion Cardiovascular Magnetic Resonance Study. *JACC Cardiovasc. Imaging.* **12**, 1699–1708 (2019).
83. G. Del Monte-Nieto, M. Ramialison, A. A. S. Adam, B. Wu, A. Aharonov, G. D’Uva, L. M. Bourke, M. E. Pitulescu, H. Chen, J. L. de la Pompa, W. Shou, R. H. Adams, S. K. Harten, E. Tzahor, B. Zhou, R. P. Harvey, Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation. *Nature.* **557**, 439–445 (2018).
84. X. Xu, I. Friehs, T. Zhong Hu, I. Melnychenko, B. Tampe, F. Alnour, M. Iascone, R. Kalluri,

- M. Zeisberg, P. J. Del Nido, E. M. Zeisberg, Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. *Circ. Res.* **116**, 857–866 (2015).
85. R. O. Ramirez Flores, J. D. Lanzer, C. H. Holland, F. Leuschner, P. Most, J.-H. Schultz, R. T. Levinson, J. Saez-Rodriguez, Consensus Transcriptional Landscape of Human End-Stage Heart Failure. *J. Am. Heart Assoc.* **10**, e019667 (2021).
86. X. Liao, Y. Shen, R. Zhang, K. Sugi, N. T. Vasudevan, M. Amer Alaiti, D. R. Sweet, L. Zhou, Y. Qing, S. L. Gerson, C. Fu, A. Wynshaw-Boris, R. Hu, M. A. Schwartz, H. Fujioka, B. Richardson, M. J. Cameron, H. Hayashi, J. S. Stamler, M. K. Jain, Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E4661–E4669 (2018).
87. O. Dewald, P. Zymek, K. Winkelmann, A. Koerting, G. Ren, T. Abou-Khamis, L. H. Michael, B. J. Rollins, M. L. Entman, N. G. Frangogiannis, CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. *Circ. Res.* **96**, 881–889 (2005).
88. Eric Lindberg, Nikolay Shvetsov, Jorge Ruiz, Matthias Heinig, Antonio Miranda, & Kazumasa Kanemaru. (2022). heiniglab/DCM_heart_cell_atlas: v1.0 Release (v1.0). Zenodo. <https://doi.org/10.5281/zenodo.6720185>
89. Supplementary Materials
90. H. Zhang, A. Viveiros, A. Nikhanj, Q. Nguyen, K. Wang, W. Wang, D. H. Freed, J. C. Mullen, R. MacArthur, D. H. Kim, W. Tymchak, C. M. Sergi, Z. Kassiri, S. Wang, G. Y. Oudit, The Human Explanted Heart Program: A translational bridge for cardiovascular medicine. *Biochim. Biophys. Acta Mol. Basis Dis.* **1867** (2021), doi:10.1016/j.bbadis.2020.165995.
91. S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W. W. Grody, M. Hegde, E. Lyon, E. Spector, K. Voelkerding, H. L. Rehm, ACMG Laboratory Quality Assurance Committee, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2015).
92. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* **25**, 1754–1760 (2009).
93. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, M. A. DePristo, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
94. X. Liu, X. Jian, E. Boerwinkle, dbNSFP v2.0: A Database of Human Non-synonymous SNVs and Their Functional Predictions and Annotations. *Human Mutation.* **34** (2013), pp. E2393–E2402.

95. K. J. Karczewski, L. C. Francioli, G. Tiao, B. B. Cummings, J. Alföldi, Q. Wang, R. L. Collins, K. M. Laricchia, A. Ganna, D. P. Birnbaum, L. D. Gauthier, H. Brand, M. Solomonson, N. A. Watts, D. Rhodes, M. Singer-Berk, E. M. England, E. G. Seaby, J. A. Kosmicki, R. K. Walters, K. Tashman, Y. Farjoun, E. Banks, T. Poterba, A. Wang, C. Seed, N. Whiffin, J. X. Chong, K. E. Samocha, E. Pierce-Hoffman, Z. Zappala, A. H. O'Donnell-Luria, E. V. Minikel, B. Weisburd, M. Lek, J. S. Ware, C. Vittal, I. M. Armean, L. Bergelson, K. Cibulskis, K. M. Connolly, M. Covarrubias, S. Donnelly, S. Ferreira, S. Gabriel, J. Gentry, N. Gupta, T. Jeandet, D. Kaplan, C. Llanwarne, R. Munshi, S. Novod, N. Petrillo, D. Roazen, V. Ruano-Rubio, A. Saltzman, M. Schleicher, J. Soto, K. Tibbetts, C. Tolonen, G. Wade, M. E. Talkowski, Genome Aggregation Database Consortium, B. M. Neale, M. J. Daly, D. G. MacArthur, The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. **581**, 434–443 (2020).
96. R. Walsh, R. Buchan, A. Wilk, S. John, L. E. Felkin, K. L. Thomson, T. H. Chiaw, C. C. W. Loong, C. J. Pua, C. Raphael, S. Prasad, P. J. Barton, B. Funke, H. Watkins, J. S. Ware, S. A. Cook, Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. *Eur. Heart J.* **38**, 3461–3468 (2017).
97. W. McLaren, L. Gil, S. E. Hunt, H. S. Riat, G. R. S. Ritchie, A. Thormann, P. Flicek, F. Cunningham, The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
98. N. Whiffin, R. Walsh, R. Govind, M. Edwards, M. Ahmad, X. Zhang, U. Tayal, R. Buchan, W. Midwinter, A. E. Wilk, H. Najgebauer, C. Francis, S. Wilkinson, T. Monk, L. Brett, D. P. O'Regan, S. K. Prasad, D. J. Morris-Rosendahl, P. J. R. Barton, E. Edwards, J. S. Ware, S. A. Cook, CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation. *Genet. Med.* **20**, 1246–1254 (2018).
99. E. R. Nadelmann, J. M. Gorham, D. Reichart, D. M. Delaughter, H. Wakimoto, E. L. Lindberg, M. Litviňukova, H. Maatz, J. J. Curran, D. Ischiu Gutierrez, N. Hübner, C. E. Seidman, J. G. Seidman, Isolation of Nuclei from Mammalian Cells and Tissues for Single-Nucleus Molecular Profiling. *Curr Protoc.* **1**, e132 (2021).
100. F. Cunningham, P. Achuthan, W. Akanni, J. Allen, M. R. Amode, I. M. Armean, R. Bennett, J. Bhai, K. Billis, S. Boddu, C. Cummins, C. Davidson, K. J. Dodiya, A. Gall, C. G. Girón, L. Gil, T. Grego, L. Haggerty, E. Haskell, T. Hourlier, O. G. Izuogu, S. H. Janacek, T. Juettemann, M. Kay, M. R. Laird, I. Lavidas, Z. Liu, J. E. Loveland, J. C. Marugán, T. Maurel, A. C. McMahon, B. Moore, J. Morales, J. M. Mudge, M. Nuhn, D. Ogeh, A. Parker, A. Parton, M. Patricio, A. I. Abdul Salam, B. M. Schmitt, H. Schuilenburg, D. Sheppard, H. Sparrow, E. Stapleton, M. Szuba, K. Taylor, G. Threadgold, A. Thormann, A. Vullo, B. Walts, A. Winterbottom, A. Zadissa, M. Chakiachvili, A. Frankish, S. E. Hunt, M. Kostadima, N. Langridge, F. J. Martin, M. Muffato, E. Perry, M. Ruffier, D. M. Staines, S. J. Trevanion, B. L. Aken, A. D. Yates, D. R. Zerbino, P. Flicek, Ensembl 2019. *Nucleic Acids Res.* **47**, D745–D751 (2018).
101. A. T. L. Lun, S. Riesenfeld, T. Andrews, T. P. Dao, T. Gomes, participants in the 1st Human Cell Atlas Jamboree, J. C. Marioni, EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. *Genome Biol.* **20**, 63 (2019).

102. F. A. Wolf, P. Angerer, F. J. Theis, SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* **19**, 15 (2018).
103. Y. Hao, S. Hao, E. Andersen-Nissen, W. M. Mauck, S. Zheng, A. Butler, M. J. Lee, A. J. Wilk, C. Darby, M. Zagar, P. Hoffman, M. Stoeckius, E. Papalexi, E. P. Mimitou, J. Jain, A. Srivastava, T. Stuart, L. B. Fleming, B. Yeung, A. J. Rogers, J. M. McElrath, C. A. Blish, R. Gottardo, P. Smibert, R. Satija, Integrated analysis of multimodal single-cell data. *Cold Spring Harbor Laboratory* (2020), p. 2020.10.12.335331.
104. Solo: Doublet Identification in Single-Cell RNA-Seq via Semi-Supervised Deep Learning. *Cell Systems.* **11**, 95–101.e5 (2020).
105. Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data. *Cell Systems.* **8**, 281–291.e9 (2019).
106. I. Korsunsky, N. Millard, J. Fan, K. Slowikowski, F. Zhang, K. Wei, Y. Baglaenko, M. Brenner, P.-R. Loh, S. Raychaudhuri, Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat. Methods.* **16**, 1289–1296 (2019).
107. V. A. Traag, L. Waltman, N. J. van Eck, From Louvain to Leiden: guaranteeing well-connected communities. *Sci. Rep.* **9**, 5233 (2019).
108. V. D. Blondel, J.-L. Guillaume, R. Lambiotte, E. Lefebvre, Fast unfolding of communities in large networks. *Journal of Statistical Mechanics: Theory and Experiment.* **2008** (2008), p. P10008.
109. A. Gayoso, R. Lopez, G. Xing, P. Boyeau, K. Wu, M. Jayasuriya, E. Melhman, M. Langevin, Y. Liu, J. Samaran, G. Misrachi, A. Nazaret, O. Clivio, C. Xu, T. Ashuach, M. Lotfollahi, V. Svensson, E. da Veiga Beltrame, C. Talavera-López, L. Pachter, F. J. Theis, A. Streets, M. I. Jordan, J. Regier, N. Yosef, scvi-tools: a library for deep probabilistic analysis of single-cell omics data, , doi:10.1101/2021.04.28.441833.
110. M. D. Robinson, D. J. McCarthy, G. K. Smyth, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* **26**, 139–140 (2010).
111. D. J. McCarthy, Y. Chen, G. K. Smyth, Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res.* **40**, 4288–4297 (2012).
112. J. Lause, P. Berens, D. Kobak, Analytic Pearson residuals for normalization of single-cell RNA-seq UMI data. *Genome Biol.* **22**, 258 (2021).
113. C. Hafemeister, R. Satija, Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol.* **20**, 296 (2019).
114. J.-A. Martín-Fernández, K. Hron, M. Templ, P. Filzmoser, J. Palarea-Albaladejo, Bayesian-multiplicative treatment of count zeros in compositional data sets. *Statistical Modelling.* **15** (2015), pp. 134–158.

115. U. Raudvere, L. Kolberg, I. Kuzmin, T. Arak, P. Adler, H. Peterson, J. Vilo, g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res.* **47**, W191–W198 (2019).
116. G. Yu, Q.-Y. He, ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. *Mol. Biosyst.* **12**, 477–479 (2016).
117. J. Díez, D. Walter, C. Muñoz-Pinedo, T. Gabaldón, DeathBase: a database on structure, evolution and function of proteins involved in apoptosis and other forms of cell death. *Cell Death Differ.* **17**, 735–736 (2010).
118. T. Shiina, K. Hosomichi, H. Inoko, J. K. Kulski, The HLA genomic loci map: expression, interaction, diversity and disease. *J. Hum. Genet.* **54**, 15–39 (2009).
119. A. Kassner, C. Oezpeker, J. Gummert, A. Zittermann, A. Gärtner, J. Tiesmeier, H. Fox, M. Morshuis, H. Milting, Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with end-stage heart failure. *European Journal of Heart Failure.* **23** (2021), pp. 324–334.
120. J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D. J. White, V. Hartenstein, K. Eliceiri, P. Tomancak, A. Cardona, Fiji: an open-source platform for biological-image analysis. *Nat. Methods.* **9**, 676–682 (2012).
121. S. Preibisch, S. Saalfeld, P. Tomancak, Globally optimal stitching of tiled 3D microscopic image acquisitions. *Bioinformatics.* **25**, 1463–1465 (2009).
122. D. Schapiro, A. Sokolov, C. Yapp, J. L. Muhlich, J. Hess, J.-R. Lin, Y.-A. Chen, M. K. Nariya, G. J. Baker, J. Ruokonen, Z. Maliga, C. A. Jacobson, S. L. Farhi, D. Abbondanza, E. T. McKinley, C. Betts, A. Regev, R. J. Coffey, L. M. Coussens, S. Santagata, P. K. Sorger, MCMICRO: A scalable, modular image-processing pipeline for multiplexed tissue imaging, doi:10.1101/2021.03.15.435473.
123. <https://github.com/HMS-IDAC/Cypository>, Version 1.1.5
124. He, K., Gkioxari, G., Dollar, P., Girshick, R., Mask R-CNN (2017), (available at <https://doi.org/10.48550/arXiv.1703.06870>)
125. Tsung-Yi Lin, Michael Maire, Serge Belongie, Lubomir Bourdev, Ross Girshick, James Hays et al., Microsoft COCO: Common Objects in Context (2015), (available at <https://doi.org/10.48550/arXiv.1405.0312>)
126. <https://github.com/HMS-IDAC/S3segmenter>, Version 1.3.18
127. M. M. Bronstein, J. Bruna, Y. LeCun, A. Szlam, P. Vandergheynst, Geometric Deep Learning: Going beyond Euclidean data. *IEEE Signal Processing Magazine.* **34** (2017), pp. 18–42.
128. P. Veličković, G. Cucurull, A. Casanova, A. Romero, P. Liò, Y. Bengio, Graph Attention

Networks (2017), (available at <http://arxiv.org/abs/1710.10903>).

129. C. Xu, R. Lopez, E. Mehlman, J. Regier, M. I. Jordan, N. Yosef, Probabilistic harmonization and annotation of single-cell transcriptomics data with deep generative models. *Mol. Syst. Biol.* **17**, e9620 (2021).

Acknowledgements:

The authors extend their heartfelt gratitude to the patients and relatives who provided cardiac tissues for research and to the biobanks who supported these efforts (Biobank of the Heart and Diabetes Center NRW, University Hospital of the Ruhr-University Bochum, the HELP Program (Mazankowski Alberta Heart Institute) and HOPE program (University of Alberta Hospital), the Cardiovascular Research Centre Biobank at the Royal Brompton and Harefield hospitals and NHS Blood and Transplant, and the Brigham and Women's Cardiovascular Tissue Bank. We also thank Hans-Peter Rahn of the Flow Cytometry Technology Platform, the Systems Biology Imaging Platform (both MDC), Tatiana Borodina of the BIH/MDC Genomics Technology Platform, and Sabine Schmidt (MDC) for technical help in single nuclei isolation and library preparation, the Facility for Imaging by Light Microscopy and Stephen Rothery (Imperial College London), the LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility for support, Lorraine Lawrence from the Research Histology Facility at Imperial College, the Biopolymers Laboratory, Paula Montero Llopis of the Microscopy Resources on the North Quad (MicRoN) core (Harvard Medical School), and Greg Plummer at the Faculty of Medicine & Dentistry Cell Imaging Core (University of Alberta) for the technical support. We thank Dr. Dagmar Keinmüller for advice on machine learning and Susanne Bartlett (Brigham and Women's Hospital and Harvard Medical School) for administrative assistance.

This article is subject to HHMI's Open Access to Publications policy. HHMI lab heads have previously granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to HHMI in their research articles. Pursuant to those licenses, the author-accepted manuscript of the article can be made freely available under a CC By 4.0 license immediately upon publication.

Funding:

This project has been made possible in part by the Chan Zuckerberg Foundation (2019-202666) to N.H., M.H., M.N., C.E.S., J.G.S., and S.A.T., the Leducq Foundation (16CVD03) to N.H., C.E.S., and J.G.S.; the British Heart Foundation and Deutsches Zentrum für Herz-Kreislauf-Forschung (BHF/DZHK: SP/19/1/34461) to N. H., M.N., and S.A.T.; the Medical Faculty of the Ruhr-University, FoRUM (F842R-2015) to H.Mi., A.G. & J.G.; the Deutsche Forschungsgemeinschaft to H.Mi. (1164,6-1, and 1146,2-2), to N.H. (SFB-1470 –

B03) and to D.R. (Research Fellowship); the Wellcome Trust (107469/Z/15/Z; 200990/A/16/Z) to J.S.W. and to S.A.T. (206194, 108413/A/15/D), the Medical Research Council (UK), the National Institute for Health Research (NIHR) Royal Brompton Cardiovascular Biomedical Research Unit and NIHR Imperial College Biomedical Research Centre to J.S.W. and P.J.B.; the National Institutes of Health (HL080494 and HL084553) to C.E.S. and J.G.S and to Y.K. (KL2-TR002542); the Engineering Research Centers Program of the National Science Foundation (NSF Cooperative Agreement EEC-1647837) to C.E.S. and J.G.S.; the John S. LaDue Fellowship of Harvard Medical School to Y.K. and K.B.; the Wellcome Trust Clinical PhD Fellowship to J.C.; the Overseas Research Fellowship of the Takeda Science Foundation to K.K., the Stanley Sarnoff Foundation Fellowship to E.R.N.; Boehringer Ingelheim Fonds to V.S.; the Brigham and Women's Hospital Khoury Innovation Award to Y.K.; the Ludwig Institute for Cancer Research grant, National Cancer Institute grant (U54-CA225088) and CCSP Supplemental Award to C.Y.; the British Heart Foundation (RE/18/4/34215) to J.S.W; the ERC-advanced grant under the European Union Horizon 2020 Research and Innovation Program (AdG788970) to N.H.; the University of Alberta Hospital Foundation (UHF), the Canadian Institute of Health Research (CIHR), the Heart and Stroke Foundation (HSF), and the Canada Research Chair in Heart Failure to G.Y.O.; the Choudhrie Family Fund and Howard Hughes Medical Institute to C.E.S.

Author Contributions:

Conceptualization: M.H., N.H., H.Ma., H.Mi., M.N., G.Y.O., C.E.S. J.G.S.

Methodology: M.H., N.H., E.L.L., H.Ma., H.Mi, M.N., G.Y.O., D.R., C.E.S., J.G.S.

Patient recruitment, clinical data analyses, tissue procurement, patient genotyping, and biobanking: P.J.R.B., R.A.C., A.Gä., L.M., H.Mi., Y.K., B.M., M.N., G.Y.O., C.E.S., P.I.T., A.v.d.B., J.S.W.

Sample processing (tissue preparation, nuclei isolation, library prep, sequencing): R.J.B., D.R.D, L.E.F., J.M.G., A.Gh., E.L.L., Y.A.L., L.M., D.R., G.P., V.S., J.G.S, A.V., H.W. H.Z.,

Data Analysis:

CM: D.R., C.E.S., J.G.S.

FB: E.A., N.H., M.K., E.L.L., H.Ma.

EC: A.M.A.M., M.N., C.L.W.

Myeloid: N.H., M.K., E.L.L., H.Ma.

Lymphoid: J.C., K.K., R.L., S.A.T.

MC: N.H. M.K., E.L.L., H.Ma., J.R.-O.,

NC: E.R.N. D.R., C.E.S., J.G.S.

Adipocytes: M.L., M.N.

Compositional: M.H., F.S., F.J.T., J.G.S.

Data interpretation: All

Histology, Immunostaining, Single molecule *in situ* hybridization, Microscopy: K.B., S.N.B., E.L.L., A.M.A.M., E.R.N., D.R., V.S., A.V., H.W., A.W., H.Z.

GWAS: P.J.R.B., M.H.

CellChat: M.L., A.M.A.M., M.N.

GAT: E.L.L., C.L., N.S.

Online data hosting: M.H.

Writing: E.A., N.H., E.L.L., M.L., A.M.A.M., H.Ma., E.R.N., D.R., J.R.-O., N.S., C.E.S., J.G.S.

Review and editing: E.A., P.J.R.B., N.H., E.L.L., H.Ma., H.Mi., M.N., G.Y.O., D.R., C.E.S. J.G.S.

Supervision: P.J.R.B., M.H., N.H., H.Ma., H.Mi., M.N., G.Y.O., C.E.S., J.G.S., S.A.T., F.T.

Funding: P.J.R.B., M.H., N.H., H.Mi., M.N., G.Y.O., C.E.S. J.G.S., S.A.T., J.S.W.

Competing Interests:

The following authors report competing interests. Consultancy Fees: J.S.W. (MyoKardia Inc, and Foresite Labs); C.E.S. and J.G.S. (Maze, BridgeBio, Bristol Myers Squibb); S.A.T. (Genentech and Roche). Scientific Advisory Boards: S.A.T. (Biogen, GlaxoSmithKline, Qiagen and Foresite Labs); Board of Directors: C.E.S. (Burroughs Wellcome Fund (U.S.) and Merck); Co-founder and equity holder: S.A.T. (Transition Bio). J.S.W. acknowledges research support from MyoKardia, Bristol Myers Squibb, and Pfizer (formerly Array BioPharma). These companies were not involved in any aspect of the study's experimental design, execution, and analyses or in the preparation of the manuscript.

D.R., E.L.L., H.M., A.M.A.M., A.V., N.S., A.G., E.R.N., M.L., K.K., J.R.-O., V.S., D.M.D., G.P., H.Z., A.W., C.L., Y.K., E.A., J.M.G., S.N.G., K.B., R.J.B., R.A.C., C.C., J.C.,

L.E.F., H.F., A.G., J.G., M.K., R.L., L.M., B.M., S.S., F.S., C.Y., C.S., P.I.T., F.J.T., A.v.d.B., H.W., C.L.W., P.J.R.B., Y.A.L., H.M., M.N., G.Y.O., M.H., N.H. declare no competing interests.

Data and Materials Availability:

Data

All sequence data generated and analyzed in this study has been deposited as BAM files at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001006374 (<https://ega-archive.org/studies/EGAS00001006374>).

Further information about EGA can be found on <https://ega-archive.org>, "The European Genome-phenome Archive in 2021"

(<https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkab1059/6430505>).

Processed data can be analyzed using the Cellxgene tool website:

<https://cellxgene.cziscience.com/collections/e75342a8-0f3b-4ec5-8ee1-245a23e0f7cb/private>

and are available in h5ad-format to download. Metadata sheets and patient information are available in Table S1&2.

Code

All code used to generate the figures in this publication are available on github (https://github.com/heiniglab/DCM_heart_cell_atlas). Code used to reproduce the presented analyses is indexed on Zenodo (88). All scripts run on jupyter notebooks are available as ".ipynb" files, scripts executed in command line are available as .txts or .sh files. R scripts are available as ".R". Anaconda environments are available as yml files containing information on package versions.

Supplementary Materials:

1. Materials and Methods
2. Figs. S1 to S52
3. Legends for Tables S1 to S71 (provided in Excel format)
4. References (90-129)

Figure legends

Figure 1: PVs and unexplained causes of DCM and ACM alter cardiac morphology, histopathology, and cellular compositions

(A) Comparisons of normal cardiac anatomy and histology to DCM, demonstrated LV dilation with fibrosis, and to ACM revealed RV dilation with fibrofatty degeneration (Masson trichrome staining, bar 10 μ m). (B) Schematic depiction of the functions of DCM and ACM genes with PVs (number indicates unique genotypes, bolded denotes ≥ 6 patients) in studied tissues. (C) Single nuclei isolated from transmural LV (free wall, apex, or septum) and RV sections were processed using 10X Chromium 3' chemistry. UMAP embedding of 881,081 nuclei delineated ten cell types and unassigned populations (gray). (D) Upper panel: Mean abundance (%) of cell types in control LVs. Lower panel: Proportional changes of cell types in specified genotypes or aggregated across DCM genotypes. Proportional changes are scaled by color: increased (red) or decreased (blue) in disease versus control. *P*-values are indicated for significant proportional changes, $FDR \leq 0.05$. (E) Pairwise cell type abundance ratios in specified genotypes or aggregated DCM genotypes in LVs relative to controls. Color scale, FDR, significance depicted as in (D).

Figure 2: Cardiomyocytes and fibroblast states in control, DCM, and ACM ventricles (A) UMAP depicting CM states in all tissues. **(B)** Control and disease LV and RV abundance analyses for vCM1.1 (upper panel) and vCM1.2 (lower panel). **(C)** Single-molecule RNA fluorescent *in situ* hybridization exemplifies decreased *SMYD1* (red) expression in CMs (identified by *TNNT2* transcripts, cyan) within a DCM heart with a PV in *PLN* (phospholamban). Cell boundaries, WGA-stained (green); nuclei DAPI-stained (blue); bar 10 μ m. Quantified expression (spots per CM) and *p*-values from four independent control and disease LVs with PVs were assessed. **(D)** Immunohistochemistry validated decreased *SMYD1* (red) protein in CMs (identified by troponin T staining, Fig. S6E) in TTN LV section. Cell boundaries, WGA-stained (green); nuclei DAPI-stained (blue); bar 10 μ m. Quantified protein levels (intensity per CM) and *p*-values were assessed from five independent control and DCM LVs with PVs. **(E)** Single-molecule RNA fluorescent *in situ* hybridization demonstrated increased expression of *FNIP2* (red). CMs, nuclei, and cell boundaries are labeled as in C; bar 10 μ m. Quantified expression of *FNIP2* (spots per CM and H-score) and *p*-values reflect analyses of two independent control and *PKP2* samples. **(F)** UMAP depicting FB states. **(G)** Hydroxyproline assay (HPA) quantified cardiac collagen content for each genotype. **(H)** Control and disease LVs and RVs abundance analyses for vFB2 (upper panel) and vFB3 (lower panel). **(I)** Pathway score of TGF β activation in LV vFB2. **(J)** Single-molecule RNA fluorescent *in situ* hybridization showed decreased expression of *CCL2* (red) in vFB3 (DCN, cyan) in disease compared to controls. WGA-stained (green); Nuclei DAPI-stained (blue); bar 10 μ m. Dot plot illustrating fold-change (\log_2FC) and significance ($-\log_{10}(FDR)$) of *CCL2* expression in LV vFB3 across genotypes.

Figure 3: Mural and endothelial cell states in control, DCM, and ACM hearts

(A) UMAP depicting pericyte (PC) and smooth muscle cell (SMC) states in all tissues. (B) Dot plots illustrate levels (fold-change; logFC) and significance ($-\log_{10}(\text{FDR})$) of selected DEGs in LV PC1, SMC1.2, SMC2, and MC (PC and SMC) across genotypes. (C) KEGG pathway analysis of DEGs in SMC2 among genotypes with ≥ 1 enriched pathways. Color intensity denotes enrichment significance ($-\log_{10}(\text{FDR})$). (D) UMAP depicting EC states in all tissues. (E) Single-molecule RNA fluorescent *in situ* hybridization identified *BMP6* (red) expression in the RV endocardium from a heart with a *DSP* (desmoplakin) PV compared to control RV. Cell boundaries, WGA-stained (green); Nuclei DAPI-stained (blue); Bar 10 μm . (F) Pairwise cell state abundance ratios in DCM LVs relative to controls. Proportional changes are scaled by color: increased (red) or decreased (blue) in disease versus control. *P*-values are indicated for significant proportional changes, $\text{FDR} < 0.05$. (G) Dot plots illustrate LV and RV levels (fold-change; logFC) and significance ($-\log_{10}(\text{FDR})$) of selected DEGs in EC7 across genotypes. Dot size and color are defined in (B).

Figure 4: Immune cell states in control, DCM, and ACM hearts

(A) UMAP depicting myeloid states in all tissues. Unclassified MP1, 2, and 3 require future characterization. Gray boxes enclosing proliferating (prolif) MPs, unclassified MPs, and cDC1s indicate that these were manually moved toward other states for ease of representation. The unmodified UMAP is in Fig. S23. (B) Myeloid prolif had higher abundance (% total myeloids) in controls versus disease. *p*-values indicate significant differences in abundances. (C) Single-molecule RNA fluorescent *in situ* hybridization validated increased expression of *TOP2A* (red) and *CIQA* (white) in controls versus disease. Cell boundaries, WGA-stained (green); Nuclei DAPI-stained (blue); Bar 10 μ m. (D) UMAP depicting lymphoid cell states in all tissues. Unclassified LY1 and 2 require future characterization. (E) Dot plots show the level of fold-change (logFC) and significance (-log₁₀(FDR)) of selected genes in LV NK CD16⁺, LV and RV CD4T^{act}, and RV CD8T^{trans} across genotypes. (F) Dot plots highlight gene expression of the Th1, 2 and 17 signatures in CD4T^{act} cells. Dot size, fraction (%) of expressing cells; color, mean expression.

Figure 5: Neuronal and adipocyte cell states in control, DCM, and ACM hearts

(A) UMAP depicting NC states in all tissues. (B) Dot plot highlighted top marker genes for NC states. (C) LV and RV abundance analyses of NC1.1 and 1.2 in controls versus disease. *P*-values are indicated for significant proportional changes, $FDR \leq 0.05$. (D) Single-molecule RNA fluorescent *in situ* hybridization showed colocalization of *AJAPI* (red), and *NRXN1* (cyan) in disease (exemplified in a DCM LV with a PV in *PLN* (phospholamban), demarcating the NC1.2 state. Cell boundaries, WGA-stained (green); Nuclei DAPI-stained (blue), Bar 10 μ m. (E) UMAP depicting AD states in all tissues. (F) Dot plot highlighted top marker genes for AD states. (G) LVs and RVs abundance analyses demonstrated decreased AD1.0 and increased AD1.1 in disease versus control. (H) Dot plot of DEGs showed expression differences between AD states. (I) Heatmap of significantly enriched Gene Ontology Biological Processes terms based on upregulated genes in diseased versus control ADs. Dot plots: Dot size, fraction (%) of expressing cells; color, mean expression level. *P*-values indicate significant differences; $FDR \leq 0.05$.

Figure 6: Altered cell-cell interactions and recognition of genotype-specific transcriptional responses

Heatmaps depict shared (A) and unique (B) signaling pathways in LVs, with significantly different expression in genotypes compared to controls. Signaling pathways are defined in the CellChat database (75). Changes in interaction strength ($\log_2(\text{fold-change})$; Table S68), scaled by color intensity (red, increased; blue, decreased). *denotes significance; adjusted p -values ≤ 0.05 ; - denotes expression was not detected in control or disease. (C) Circle plots of significant (adjusted p -value ≤ 0.05) cell-cell communication depict differentially regulated IGF, BMP, and NRG pathways and interactions in disease LVs. The line thickness denotes interaction strength of signals from sending and receiving cell; with color scaled from zero to maximum in disease versus controls (orange, increased; blue, decreased). Arrows indicate directionality. (D) (Top) Genotype prediction probability from graph attention networks (GAT) per cell type. (Bottom) Stacked bar plots represent the likelihood (% aggregated probability) of individual patient genotypes by GAT prediction. Most established genotypes were predicted with high probability, with lower prediction probability only in H10 (*PKP2*), H20 (*RBM20*), H22 (*RBM20*) and H33 (*RBM20*).

